CBL-514 Explained: The Fat-Cell Apoptosis Injection Now in Phase 3

CBL-514 is a first-in-class injectable developed by Caliway Biopharmaceuticals (TWSE: 6919), a company founded in 2012 in New Taipei and listed on the Taiwan Stock Exchange since October 2024. Caliway describes it as a patented small-molecule product developed under the FDA's 505(b)(1) pathway – the route for a new drug backed by the sponsor's own full safety and efficacy package rather than by reference to an existing approved product. The lead indication is the reduction of abdominal subcutaneous fat. Separate programmes target cellulite, the rare disorder Dercum's disease and, in combination with incretin drugs, weight regain.

The idea is injection lipolysis without tissue destruction. Instead of dissolving fat cells chemically, CBL-514 is designed to make them dismantle themselves. Caliway states that the product reduces fat at the injection site without causing necrosis or damage to surrounding tissue. That claim, like every efficacy and safety statement in this article, comes from the sponsor and is being tested in Phase 3.

Caliway's press material rarely names the chemistry, but its trial protocols do. The protocol of the pharmacokinetic study CBL-0203 (NCT05234736, version 1.0, 18 October 2021) lists the active pharmaceutical ingredients as curcumin (CAS 458-37-7) and trans-resveratrol (CAS 501-36-0). They are processed into a drug substance called "CBL-514 powder" and supplied in 20 mL glass vials. The concentration of each component is redacted in the public document. The same protocol attributes the temporary yellow skin discoloration seen at injection sites in early trials to curcumin, a natural yellow pigment.

Two things follow. First, CBL-514 is not a peptide, even though it circulates in peptide forums under names such as "CBL peptide". Second, its novelty does not lie in the molecules – both are well-characterised natural products – but in the fixed combination, the ratio, the solubilisation of two poorly water-soluble polyphenols into an injectable, and the clinical data generated with that exact formulation. One of Caliway's US patents (11,433,034) describes curcumin encapsulated in surfactant micelles for reducing localised fat, which shows where the company sees the technical problem.

According to the Phase 2 protocol CBL-0202 (NCT04575467), CBL-514 triggers adipocyte apoptosis by inhibiting DYRK1B, a kinase that supports cell survival. Blocking it increases caspase-3 expression and raises the Bax/Bcl-2 ratio, two standard markers that tip a cell towards programmed death. Caliway's nonclinical work reported adipocyte apoptosis in vitro and in animal models, and the first peer-reviewed human study – a randomised Phase IIa trial published in Aesthetic Surgery Journal in 2022 – described reductions in abdominal fat volume and thickness consistent with that mechanism.

The difference from older injectables is the mode of cell death. Apoptosis is an orderly process: the cell condenses and is cleared by macrophages. Detergent-type agents such as deoxycholic acid (Kybella) instead rupture cell membranes on contact, which causes necrosis and a marked local inflammatory response. Caliway argues that this is why CBL-514 can be used over large areas such as the abdomen. Our comparison of CBL-514 and Kybella looks at that argument in detail.

A second consequence matters for metabolic research. Apoptosis reduces the number of fat cells, whereas calorie restriction and incretin drugs mainly shrink existing ones. Because fat-cell number in adults is relatively stable, Caliway is now testing whether removing adipocytes can reduce weight regain after GLP-1 therapy ends.

ClinicalTrials.gov lists 16 study records for CBL-514 (queried 3 November 2026). The table groups them by stage; status and enrolment targets are as registered.

The Phase 3 design rests on two completed Phase 2b trials, CBL-0204 and CBL-0205. Full peer-reviewed publications were not available at the time of writing, so the figures below are Caliway's own summaries of CBL-0205 in the full analysis set.

In July 2026 Caliway also reported that 24–32% of CBL-514 participants reached a 2-grade improvement on the patient-reported abdominal fat rating scale (PR-AFRS) alone and 23–30% on the clinician-reported scale (CR-AFRS), against 0–2.5% on placebo, four weeks after the last treatment. The company compares these figures with historical responder rates from the pivotal programmes of Kybella and the withdrawn cellulite injectable Qwo, while acknowledging that indications and study designs differ. Cross-trial comparisons of this kind are indicative at best.

Safety data from the early studies describe mostly mild-to-moderate injection-site reactions: bruising, redness, swelling, warmth, itching and the temporary yellow discoloration. Caliway states that more than 544 people have taken part in CBL-514 trials and that all ten studies with finalised statistical reports met their primary and key secondary endpoints.

SUPREME-01 (CBL-0301) is a randomised, double-blind, placebo-controlled trial planned for about 320 participants at 25–30 sites in the United States and Canada. Caliway announced on 23 September 2026 that the first participant had been dosed. After discussions with the FDA, the primary endpoint was made stricter: a responder must improve by at least two grades on both the patient-reported and the clinician-reported scale four weeks after the last treatment. MRI-measured change in fat volume became a key secondary endpoint.

SUPREME-02 (CBL-0302) follows the same basic design with about 320 participants in the United States, Canada and Australia; its IND passed the FDA's 30-day review on 18 May 2026. In the May announcement its primary endpoints were MRI-measured fat volume and the patient-reported scale. CBL-0303, registered for 300 participants, is designed to extend both pivotal trials and track whether the effect lasts. An Asia-Pacific Phase 2 study (CBL-0206, about 250 participants in Taiwan and Australia) is enrolling, and Caliway has said it is preparing a Phase 3 application in China.

Caliway expects topline Phase 3 results in 2027, to support a New Drug Application. There is no filing date and no approval decision yet; any timeline beyond 2027 is projection, not fact.

Dercum's disease (adiposis dolorosa) is a rare disorder marked by painful fatty tissue and lipomas, with no approved drug treatment. A separate formulation, CBL-514D, holds FDA Orphan Drug and Fast Track designations and an EMA orphan designation for it. On 23 September 2026 Caliway reported that the placebo-controlled Phase 2 trial CBL-0202DD met its primary endpoint, with statistically significant pain reduction versus placebo in both analysis populations.

In cellulite, the two-stage Phase 2 study CBL-0201EFP met its primary and secondary endpoints, according to the company. In metabolic research, Caliway has FDA clearance for a Phase 2 trial combining CBL-514 with tirzepatide (CBL-0201WR, about 120 participants) to test whether removing fat cells limits regain after treatment stops. Our article on CBL-514 and GLP-1 drugs covers that programme.

• Not approved: no regulator has authorised CBL-514 for any use.
• Not a peptide: its disclosed active ingredients are two small-molecule polyphenols.
• Not available as a reference material: Caliway has not published the ratio, the formulation or a reference standard, so material sold online under the name cannot be verified as the clinical product.
• Not interchangeable with supplements: oral curcumin or resveratrol products are a different dosage form and say nothing about the trial results.

CBL-514 is an investigational injectable drug from Caliway Biopharmaceuticals designed to reduce subcutaneous fat at the injection site by inducing apoptosis in fat cells. It is in Phase 3 trials for abdominal fat reduction and in Phase 2 for cellulite and Dercum's disease.

No. As of November 2026 CBL-514 is in Phase 3 trials. Caliway expects topline results in 2027 and plans to file a New Drug Application afterwards. No regulator has approved it.

The CBL-0203 trial protocol names curcumin (CAS 458-37-7) and trans-resveratrol (CAS 501-36-0) as the active pharmaceutical ingredients. The ratio, the concentrations and the excipients are not public.

According to Caliway's protocols, CBL-514 inhibits the survival kinase DYRK1B. This raises caspase-3 expression and the Bax/Bcl-2 ratio and drives fat cells into apoptosis, which reduces the number of fat cells rather than their size.

Kybella contains deoxycholic acid, a detergent that ruptures cell membranes (cytolysis). CBL-514 is designed to trigger programmed cell death instead. Kybella has been FDA-approved since 2015 for fat under the chin; CBL-514 is investigational and is being studied for larger areas such as the abdomen.

Not before both pivotal Phase 3 trials report and an application has been reviewed. Caliway expects Phase 3 topline data in 2027 and has given no launch date; earlier dates are speculation.